173 related articles for article (PubMed ID: 8248084)
41. Glycation of collagen: the basis of its central role in the late complications of ageing and diabetes.
Paul RG; Bailey AJ
Int J Biochem Cell Biol; 1996 Dec; 28(12):1297-310. PubMed ID: 9022289
[TBL] [Abstract][Full Text] [Related]
42. The effects of the Maillard reaction on the physical properties and cell interactions of collagen.
Avery NC; Bailey AJ
Pathol Biol (Paris); 2006 Sep; 54(7):387-95. PubMed ID: 16962252
[TBL] [Abstract][Full Text] [Related]
43. [Glycation and protein crosslinking in the diabetes and ageing pathogenesis].
Cárdenas-León M; Díaz-Díaz E; Argüelles-Medina R; Sánchez-Canales P; Díaz-Sánchez V; Larrea F
Rev Invest Clin; 2009; 61(6):505-20. PubMed ID: 20184132
[TBL] [Abstract][Full Text] [Related]
44. Kinetics of nonenzymatic glycation of ribonuclease A leading to advanced glycation end products. Paradoxical inhibition by ribose leads to facile isolation of protein intermediate for rapid post-Amadori studies.
Khalifah RG; Todd P; Booth AA; Yang SX; Mott JD; Hudson BG
Biochemistry; 1996 Apr; 35(15):4645-54. PubMed ID: 8664253
[TBL] [Abstract][Full Text] [Related]
45. Renal catabolism of advanced glycation end products: the fate of pentosidine.
Miyata T; Ueda Y; Horie K; Nangaku M; Tanaka S; van Ypersele de Strihou C; Kurokawa K
Kidney Int; 1998 Feb; 53(2):416-22. PubMed ID: 9461101
[TBL] [Abstract][Full Text] [Related]
46. [Maillard reaction products and chronic diabetic complications].
Trivin F; Chevenne D; Hautecouverture M
Ann Biol Clin (Paris); 1999; 57(4):445-54. PubMed ID: 10432367
[No Abstract] [Full Text] [Related]
47. Advanced Maillard reaction end products are associated with Alzheimer disease pathology.
Smith MA; Taneda S; Richey PL; Miyata S; Yan SD; Stern D; Sayre LM; Monnier VM; Perry G
Proc Natl Acad Sci U S A; 1994 Jun; 91(12):5710-4. PubMed ID: 8202552
[TBL] [Abstract][Full Text] [Related]
48. Fructose-mediated non-enzymatic glycation: sweet coupling or bad modification.
Schalkwijk CG; Stehouwer CD; van Hinsbergh VW
Diabetes Metab Res Rev; 2004; 20(5):369-82. PubMed ID: 15343583
[TBL] [Abstract][Full Text] [Related]
49. Angiotensin II receptor blocker inhibits abnormal accumulation of advanced glycation end products and retinal damage in a rat model of type 2 diabetes.
Sugiyama T; Okuno T; Fukuhara M; Oku H; Ikeda T; Obayashi H; Ohta M; Fukui M; Hasegawa G; Nakamura N
Exp Eye Res; 2007 Sep; 85(3):406-12. PubMed ID: 17678894
[TBL] [Abstract][Full Text] [Related]
50. Advanced glycation endproducts and cigarette smoking.
Nicholl ID; Bucala R
Cell Mol Biol (Noisy-le-grand); 1998 Nov; 44(7):1025-33. PubMed ID: 9846884
[TBL] [Abstract][Full Text] [Related]
51. Modification of vimentin: a general mechanism of nonenzymatic glycation in human skin.
Kueper T; Grune T; Muhr GM; Lenz H; Wittern KP; Wenck H; Stäb F; Blatt T
Ann N Y Acad Sci; 2008 Apr; 1126():328-32. PubMed ID: 18448838
[TBL] [Abstract][Full Text] [Related]
52. Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS.
Seftel AD; Vaziri ND; Ni Z; Razmjouei K; Fogarty J; Hampel N; Polak J; Wang RZ; Ferguson K; Block C; Haas C
Urology; 1997 Dec; 50(6):1016-26. PubMed ID: 9426743
[TBL] [Abstract][Full Text] [Related]
53. Advanced glycation end products overload might explain intracellular cobalamin deficiency in renal dysfunction, diabetes and aging.
Obeid R; Shannan B; Herrmann W
Med Hypotheses; 2011 Nov; 77(5):884-8. PubMed ID: 21880434
[TBL] [Abstract][Full Text] [Related]
54. Advanced glycation end products in children with chronic renal failure and type 1 diabetes.
Misselwitz J; Franke S; Kauf E; John U; Stein G
Pediatr Nephrol; 2002 May; 17(5):316-21. PubMed ID: 12042886
[TBL] [Abstract][Full Text] [Related]
55. Effects of model Maillard compounds on bone characteristics and functionality.
Roncero-Ramos I; Delgado-Andrade C; Rufián-Henares JÁ; Carballo J; Navarro MP
J Sci Food Agric; 2013 Aug; 93(11):2816-21. PubMed ID: 23420603
[TBL] [Abstract][Full Text] [Related]
56. Natural compounds containing a catechol group enhance the formation of Nε-(carboxymethyl)lysine of the Maillard reaction.
Fujiwara Y; Kiyota N; Tsurushima K; Yoshitomi M; Mera K; Sakashita N; Takeya M; Ikeda T; Araki T; Nohara T; Nagai R
Free Radic Biol Med; 2011 Apr; 50(7):883-91. PubMed ID: 21195168
[TBL] [Abstract][Full Text] [Related]
57. Pharmacological prevention of cardiovascular aging--targeting the Maillard reaction.
Aronson D
Br J Pharmacol; 2004 Aug; 142(7):1055-8. PubMed ID: 15237100
[TBL] [Abstract][Full Text] [Related]
58. [Protein glycation--clinical and chemical aspects].
Szymańska U; Boratyński J
Postepy Hig Med Dosw; 1999; 53(5):689-703. PubMed ID: 10645144
[TBL] [Abstract][Full Text] [Related]
59. The Maillard reaction in vivo.
Dyer DG; Blackledge JA; Katz BM; Hull CJ; Adkisson HD; Thorpe SR; Lyons TJ; Baynes JW
Z Ernahrungswiss; 1991 Feb; 30(1):29-45. PubMed ID: 1858426
[TBL] [Abstract][Full Text] [Related]
60. [Advances in the Maillard reaction and glycation researches--mainly on the Namiki pathway].
Namiki M
Seikagaku; 2003 Jan; 75(1):37-42. PubMed ID: 12645131
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
